Human ATAD5 is a biomarker for identifying genotoxic compounds because ATAD5 protein levels increase posttranscriptionally in response to DNA damage. We screened over 4,000 compounds with a cell-based quantitative high-throughput ATAD5-luciferase assay detecting genotoxic compounds. We identified 22 antioxidants, including resveratrol, genistein, and baicalein, that are currently used or investigated for the treatment of cardiovascular disease, type 2 diabetes, osteopenia, osteoporosis, and chronic hepatitis, as well as for antiaging. Treatment of dividing cells with these compounds induced DNA damage and resulted in cell death. Despite their genotoxic effects, resveratrol, genistein, and baicalein did not cause mutagenesis, which is a major side effect of conventional anticancer drugs. Furthermore, resveratrol and genistein killed multidrug-resistant cancer cells. We therefore propose that resveratrol, genistein, and baicalein are attractive candidates for improved chemotherapeutic agents.chemotherapy | high-throughput screening O ne distinctive characteristic of cancer cells is persistent cell division that requires DNA replication. This feature is often exploited to develop chemotherapeutic drugs because cancer cells are exquisitely sensitive to the inhibition of DNA replication by the introduction of DNA damage by radiation or genotoxic chemicals. DNA lesions resulting from exposure to genotoxic agents stall DNA replication, collapse replication forks, and produce DNA double-strand breaks (DSBs), resulting in cell death. If not repaired properly, many of these genomic insults can also induce gene mutations or chromosomal alterations that may make cells more resilient to cell-cycle checkpoints or apoptosis. Thus, cancer treatment may greatly benefit from the identification of genotoxic agents that kill rapidly dividing cells with minimal mutagenic side effects.ATAD5 is the homolog of yeast Enhanced Level of Genome Instability Gene 1 (ELG1), which makes a heteropentameric alternative replication factor C complex and suppresses genomic instability and tumorigenesis (1-3). ATAD5 plays a key role in the translesion synthesis (TLS) pathway where TLS polymerases are used to bypass DNA lesions that stall or collapse DNA replication forks (4, 5). In the TLS pathway, switching from replicative polymerases to TLS polymerases is promoted through the interaction between proliferating cell nuclear antigen (PCNA) monoubiquitylated at lysine 164 and an ubiquitin-binding motif in TLS polymerases, a mechanism that is conserved from yeast to humans (6). ATAD5 is stabilized and forms nuclear foci at the site of stalled replication forks in response to DNA damage (7) and appears to participate in the removal of ubiquitin from chromatinbound monoubiquitylated PCNA through its interaction with ubiquitin-specific peptidase 1 (5). The ATAD5-mediated deubiquitylation of PCNA allows lesion-bypassed TLS polymerases to switch back to replicative polymerases, and thereby prevents the low-fidelity TLS polymerases from causing harmful muta...